Luke Sergott
Stock Analyst at Barclays
(4.65)
# 893
Out of 5,184 analysts
818
Total ratings
50.3%
Success rate
10.1%
Average return
Main Sectors:
Stocks Rated by Luke Sergott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVTY Revvity | Reiterated: Hold | $175 | $145.22 | +20.51% | 37 | Nov 16, 2026 | |
| TWST Twist Bioscience | Reiterated: Buy | $215 → $130 | $103.32 | +25.82% | 43 | Nov 13, 2026 | |
| MTD Mettler-Toledo International | Reiterated: Buy | $1,700 → $1,900 | $1,666.88 | +13.99% | 12 | Nov 9, 2026 | |
| TXG 10x Genomics | Reiterated: Buy | $110 → $70 | $51.80 | +35.14% | 37 | Nov 9, 2026 | |
| CERT Certara | Reiterated: Hold | $9 → $12 | $10.55 | +13.74% | 38 | Nov 6, 2026 | |
| GH Guardant Health | Reiterated: Buy | $220 | $145.83 | +50.86% | 22 | Nov 6, 2026 | |
| NTRA Natera | Reiterated: Buy | $475 | $273.40 | +73.74% | 18 | Nov 6, 2026 | |
| BRKR Bruker | Reiterated: Buy | $70 | $56.46 | +23.98% | 22 | Nov 5, 2026 | |
| CRL Charles River Laboratories International | Reiterated: Buy | $330 → $375 | $314.32 | +19.31% | 22 | Nov 5, 2026 | |
| PACB Pacific Biosciences of California | Reiterated: Sell | $1.25 → $2 | $1.63 | +22.70% | 29 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 → $20 | $15.91 | +25.71% | 45 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $500 → $530 | $440.45 | +20.33% | 37 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $775 | $669.54 | +15.75% | 49 | Nov 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 → $26 | $18.55 | +40.16% | 24 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $200 | $192.82 | +3.72% | 53 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $440 → $500 | $390.30 | +28.11% | 13 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $15 → $16 | $14.84 | +7.82% | 48 | Oct 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $175 → $230 | $186.71 | +23.19% | 43 | Oct 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $300 | $245.82 | +22.04% | 51 | Oct 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $330 → $380 | $367.13 | +3.51% | 19 | Oct 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $225 | $163.81 | +37.35% | 14 | Oct 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $55 → $53 | $49.30 | +7.51% | 21 | Oct 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $260 | $258.28 | +0.67% | 22 | Oct 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $625 → $675 | $610.54 | +10.56% | 12 | Oct 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $255 → $260 | $220.36 | +17.99% | 49 | Oct 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $175 → $195 | $170.38 | +14.45% | 35 | Oct 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $35 → $42 | $3.83 | n/a | 2 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $200 | $218.54 | n/a | 1 | Jan 18, 2023 |
Revvity
Nov 16, 2026
Reiterated: Hold
Price Target: $175
Current: $145.22
Upside: +20.51%
Twist Bioscience
Nov 13, 2026
Reiterated: Buy
Price Target: $215 → $130
Current: $103.32
Upside: +25.82%
Mettler-Toledo International
Nov 9, 2026
Reiterated: Buy
Price Target: $1,700 → $1,900
Current: $1,666.88
Upside: +13.99%
10x Genomics
Nov 9, 2026
Reiterated: Buy
Price Target: $110 → $70
Current: $51.80
Upside: +35.14%
Certara
Nov 6, 2026
Reiterated: Hold
Price Target: $9 → $12
Current: $10.55
Upside: +13.74%
Guardant Health
Nov 6, 2026
Reiterated: Buy
Price Target: $220
Current: $145.83
Upside: +50.86%
Natera
Nov 6, 2026
Reiterated: Buy
Price Target: $475
Current: $273.40
Upside: +73.74%
Bruker
Nov 5, 2026
Reiterated: Buy
Price Target: $70
Current: $56.46
Upside: +23.98%
Charles River Laboratories International
Nov 5, 2026
Reiterated: Buy
Price Target: $330 → $375
Current: $314.32
Upside: +19.31%
Pacific Biosciences of California
Nov 5, 2026
Reiterated: Sell
Price Target: $1.25 → $2
Current: $1.63
Upside: +22.70%
Nov 4, 2026
Reiterated: Buy
Price Target: $22 → $20
Current: $15.91
Upside: +25.71%
Nov 4, 2026
Reiterated: Buy
Price Target: $500 → $530
Current: $440.45
Upside: +20.33%
Nov 2, 2026
Reiterated: Buy
Price Target: $775
Current: $669.54
Upside: +15.75%
Oct 30, 2026
Reiterated: Buy
Price Target: $23 → $26
Current: $18.55
Upside: +40.16%
Oct 30, 2026
Reiterated: Sell
Price Target: $200
Current: $192.82
Upside: +3.72%
Oct 30, 2026
Reiterated: Buy
Price Target: $440 → $500
Current: $390.30
Upside: +28.11%
Oct 29, 2026
Reiterated: Sell
Price Target: $15 → $16
Current: $14.84
Upside: +7.82%
Oct 28, 2026
Reiterated: Hold
Price Target: $175 → $230
Current: $186.71
Upside: +23.19%
Oct 28, 2026
Reiterated: Buy
Price Target: $300
Current: $245.82
Upside: +22.04%
Oct 28, 2026
Reiterated: Hold
Price Target: $330 → $380
Current: $367.13
Upside: +3.51%
Oct 28, 2026
Reiterated: Buy
Price Target: $225
Current: $163.81
Upside: +37.35%
Oct 27, 2026
Downgraded: Hold
Price Target: $55 → $53
Current: $49.30
Upside: +7.51%
Oct 23, 2026
Reiterated: Buy
Price Target: $260
Current: $258.28
Upside: +0.67%
Oct 23, 2026
Reiterated: Hold
Price Target: $625 → $675
Current: $610.54
Upside: +10.56%
Oct 22, 2026
Reiterated: Buy
Price Target: $255 → $260
Current: $220.36
Upside: +17.99%
Oct 7, 2026
Reiterated: Buy
Price Target: $175 → $195
Current: $170.38
Upside: +14.45%
Jun 12, 2023
Reiterated: Hold
Price Target: $35 → $42
Current: $3.83
Upside: n/a
Jan 18, 2023
Rated: Buy
Price Target: $200
Current: $218.54
Upside: n/a